araag2/HINT huggingface dataset:
Clinical trial NCT00555204 (phase 2, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: abt-089, abt-089, abt-089, abt-089, abt-089, abt-089, placebo
SMILES: CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has mild to moderate Alzheimer's disease

          -  Patient has been receiving a stable dose of an acetylcholinesterase inhibitor

          -  Patient has a MMSE score between 12 and 26

          -  Patient has a MHIS score of less than or equal to 4

          -  Females must be postmenopausal for at least two years or surgically sterile

          -  Patient has an identified, reliable, caregiver who will support him/her to ensure
             compliance with treatment and will accompany them to each outpatient visit

        Exclusion Criteria:

          -  Patient is living in a nursing home

          -  Patient has a history of any significant neurologic disease other than Alzheimer's
             disease

          -  Patient has any uncontrolled medical illness

          -  Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol
             abuse/dependence
Clinical trial NCT00677365 (phase 2, status: completed)
Conditions: cystic fibrosis (cf)
ICD codes: K74.01, K74.02, E84.9, J84.10, J84.112, K13.5, K74.00
Drugs: mp-376, placebo
SMILES: C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria (selected):

          -  > 16 years of age

          -  Confirmed Diagnosis of Cystic Fibrosis

          -  Positive sputum culture for P. aeruginosa within the past 18 months

          -  Patients are able to elicit a forced expiratory volume in 1 second (FEV1) >/= 25% but
             </= 85% of predicted value at screening

          -  Have received at least 3 courses of inhaled antimicrobials over the preceding 12
             months

          -  Clinically stable with no changes in health status within the last 30 days

          -  Able to reproducibly produce sputum and perform spirometry

        Exclusion Criteria (selected):

          -  Use of any nebulized or systemic antibiotics within 30 days prior to baseline

          -  History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication

          -  Evidence of acute upper within 10 days or lower respiratory infections within 30 days
             prior to dosing

          -  Creatine clearance < 50mg/ml, aspartate transaminase (AST), alanine transaminase (ALT)
             or total bilirubin >/= 3 x upper limit of normal (ULN) at Screening
Clinical trial NCT00171730 (phase 2, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: pasireotide
SMILES: NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have completed all four treatment regimens in the core study CSOM230B2201
             and achieved biochemical control in GH and IGF-1 levels after at least one month of
             pasireotide administration at any of the three doses

          -  Patients who did not experience any unacceptable adverse events or tolerability issues
             during the core study CSOM230B2201

        Exclusion Criteria:

          -  Patients who experienced or developed compression of the optic chiasm causing any
             visual field defect during the core study CSOM230B2201

          -  Patients who required a surgical intervention for relief of any sign or symptom
             associated with tumor compression during the core study CSOM230B2201 Patients who
             experienced or developed congestive heart failure, unstable angina, sustained
             ventricular tachycardia, ventricular fibrillation or acute myocardial infraction
             during the core study CSOM230B2201

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00335959 (phase 2, status: terminated)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    closed due to slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary adenocarcinoma of the stomach, meeting the following
             criteria:

               -  Newly diagnosed disease amenable to curative resection

               -  Stage IB-III (T2-4)

          -  Measurable or nonmeasurable disease

          -  Enlarged lymph nodes outside of radiation fields must have preoperative biopsies

               -  No positive lymph nodes outside of radiation fields

          -  No distant metastasis

          -  No gastroesophageal junction tumors

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  WBC ≥ 3,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 1.5 times upper limit of normal

          -  Albumin ≥ 3 g/dL

          -  Bilirubin normal

          -  No evidence of ischemic heart disease by EKG

          -  No coronary artery disease requiring active medical treatment

          -  No symptoms of angina

          -  No history of myocardial infarction

          -  No deep vein thrombosis within the past 12 months

          -  No pre-existing peripheral neuropathy

          -  No active pneumonia or inflammatory lung infiltrate

          -  No prior malignancy except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease free for ≥ 5 years

          -  No clinically significant comorbid medical conditions that would prevent delivery of
             chemotherapy, radiotherapy, or the performance of surgery

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior and no concurrent sorivudine or brivudine

          -  No prior therapy for this malignancy, including chemotherapy, surgery, immunotherapy,
             or radiotherapy

          -  No prior coronary angioplasty or stenting

          -  No concurrent 2-dimensional or intensity-modulated radiotherapy
Clinical trial NCT00226980 (phase 2, status: completed)
Conditions: kidney neoplasms
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: thalidomide, capecitabine
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent

          -  Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program.

          -  Male or female 18 years or older

          -  Willing to use contraception

          -  Pathologic diagnosis of renal cell carcinoma

          -  Bi-dimensionally measurable disease

          -  Evidence of disease progression prior to start of treatment

          -  Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy

          -  Adequate hematologic data: ANC.1.5; platelets>100x10^9

          -  Adequate renal function: Creatinine clearance .50cc

          -  Adequate liver function: Alkaline phos <3XULN AST/ALT <3XULN T.Bili <1.5XULN

          -  ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases.

          -  Peripheral neuropathy.

          -  Pregnant and/ or lactating female.

          -  Unable to take a baby aspirin.
Clinical trial NCT00333138 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: fty720, placebo
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Core Study

        Inclusion Criteria:

          -  Diagnosis of relapsing multiple Sclerosis (MS)

          -  Patients with at least two documented relapses in the previous 2 years or one
             documented relapse in the last year

          -  Patients with an Expanded Disability Status Scale (EDSS) score of 0-6

        Extension Study

          -  A positive Gd-enhanced MRI scan at screening (in case the first MRI scan obtained at
             screening was negative, a second scan could have been obtained 1 month later)

          -  Neurologically stable with no evidence of relapse within 30 days prior to
             randomization,or during the Screening and Baseline periods.

          -  Female patients either post-menopausal, surgically incapable of bearing children, or
             practicing an acceptable method of birth control. Females of childbearing potential
             with a negative pregnancy test at baseline prior to entry into the treatment period.

        Exclusion Criteria:

        Core Study

          -  Patients with other chronic disease of the immune system, malignancies, pulmonary or
             heart disease, etc

          -  Pregnant or nursing women

        Extension Study

          -  Patients who had permanently discontinued study drug prior to the Month 6 visit of the
             core study

          -  Patients with diabetes mellitus (to reduce the risk of ME), and therefore ongoing
             patients with diabetes mellitus or who developed diabetes mellitus were discontinued
             from the study)

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00478881 (phase 2, status: completed)
Conditions: overactive bladder, detrusor overactivity
ICD codes: N32.81, R46.3, E27.0
Drugs: vardenafil hcl (levitra, bay38-9456), placebo
SMILES: CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged > 18 years (females either postmenopausal or using
             adequate birth control)

          -  Urodynamic criteria:

               -  Entire bladder capacity (= maximum cystometric bladder capacity) < 300 mL OR

               -  In accordance with International Continence Society (ICS)-guidelines: Detrusor
                  overactivity as defined as spontaneous involuntary detrusor contraction during
                  filling phase OR

               -  Detrusor contraction during filling phase leading to involuntarily initiated
                  micturition before a normal bladder capacity is reached

          -  Patient micturition diary criteria: at least 8 micturitions per day AND at least 1
             urgency episode per day

          -  Signed and dated written Patient Informed Consent Form

        Exclusion Criteria:

          -  Treatment with drugs known to affect urinary bladder function

          -  Known other reasons for micturition problems than detrusor overactivity

          -  Recent intervention in urogenital tract

          -  Abnormal liver or renal lab values

          -  Treatment with nitrates or nitric oxide donors, alpha-blockers, potent inhibitors of
             CYP-450 3A4, acenocoumarol, heparin, drugs known to prolong QT-interval

          -  NAION, hereditary regenerative retinal disorders, severe cardiovascular conditions,
             recent history of myocardial infarction/stroke/life-threatening arrhythmia

          -  congenital QT-prolongation, left ventricular outflow obstruction, severe hypo- or
             hypertension, symptomatic postural hypotension

          -  History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C

          -  Significant active peptic ulceration

          -  Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe
             (Child-Pugh C) hepatic impairment

          -  In men: Clinically significant chronic haematological disease which may lead to
             priapism

          -  History of malignancy of any organ system within the past 5 years

          -  Bleeding disorder
Clinical trial NCT00223301 (phase 2/phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: mycophenolate mofetil (cellcept)
SMILES: COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
Eligibility criteria:

        Inclusion Criteria:

          1. Between the ages of 21-45 inclusive

          2. Clinically definite, laboratory supported definite relapsing MS of less than or equal
             to two years in duration or monosymptomatic MS meeting CHAMPS criteria ref .

          3. At least one exacerbation in the preceding two years

          4. Written informed consent.

        Exclusion Criteria:

          1. Primary progressive, secondary progressive or progressive relapsing MS.

          2. Corticosteroids during the 60 days prior to study entry.

          3. Treatment with plasma exchange within 90 days of preenrollment.

          4. No prior exposure to total lymphoid irradiation.

          5. No prior use of interferons, monoclonal antibodies, glatiramer acetate, methotrexate
             or other immunomodulatory drugs

          6. A clinical relapse within 60 days prior to enrollment.

          7. Pregnant/breastfeeding.

          8. Patients with major medical illnesses.

          9. Cognitive impairment interfering with ability to comply with the protocol.

         10. Patients who need to remain on any contraindicated medication.

         11. Diabetic

         12. Inability to undergo MRI scan

         13. On intravenous immunoglobulin protocol

         14. HIV+ or RPR+

         15. Females of childbearing age who have not undergone a sterilization procedure must be
             willing to practice effective birth control.
Clinical trial NCT00174941 (phase 2, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: febuxostat, febuxostat, febuxostat
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Hyperuricemia (serum uric acid ≥8.0 mg/dL upon entering parent study TMX-00-004).

          -  Must meet American College of Rheumatology criteria for gout.

          -  Must have adequate renal function (serum creatinine <1.5 mg/dL).

          -  Must have completed four weeks of double-blind dosing in Study TMX-00-004.

          -  Must not have experienced any serious study drug-related Adverse Events in Study TMX
             00-004.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

        Exclusion Criteria:

          -  History of xanthinuria

          -  Alcohol consumption >14/week

          -  Has a History of significant concomitant illness

          -  Has active liver disease.

          -  Has a body mass index greater than 50 kg/m2

          -  Any other significant medical condition that would interfere with the treatment,
             safety or compliance with the protocol, as defined by the investigator.
Clinical trial NCT00122603 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: fosamprenavir, saquinavir
SMILES: CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Protease inhibitor naive patients

          -  Wild type genotype

          -  CD4 greater than 200/mm3

          -  Viral load between 10,000 copies/ml and 750,000 copies/ml

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy; breast feeding

          -  Antiretroviral (ARV) pretreated patients

          -  Hyperlipidemic treatment

          -  Evolutive disease
Clinical trial NCT00454779 (phase 2, status: completed)
Conditions: metastatic or recurrent squamous cell carcinoma of head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cisplatin, panitumumab, docetaxel, cisplatin, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic and/or recurrent Squamous Cell
             Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or
             radiation therapy.

          -  Measurable disease by CT scan

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

          -  Age: 18 years or older

          -  Adequate hematologic, renal, metabolic, hepatic & thyroid function

        Exclusion Criteria:

          -  Prior systemic treatment for metastatic and/or recurrent SCCHN

          -  CNS metastases, or nasopharyngeal carcinoma

          -  History of interstitial lung disease

          -  History of another primary cancer

          -  Any co-morbid disease that would increase risk of toxicity

               -  Active infection requiring systemic treatment

               -  Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy
Clinical trial NCT00434135 (phase 2, status: completed)
Conditions: non-small cell lung cancer, stage iiib or iv
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed locally advanced (stage IIIB)
             or metastatic (stage IV) NSCLC

          2. No previous adjuvant or palliative chemotherapy

          3. No previous radiotherapy

          4. Presence of at least one unidimensionally measurable lesion (Appendix 2)

          5. ECOG performance status of 0 or 1 (Appendix 3)

          6. Charlson score ≤ 2 (Appendix 4)

          7. Adequate bone marrow function (absolute neutrophil count ≥ 2 x 109/L, platelet count ≥
             100 x 109/L, and hemoglobin level ≥ 100 g/L), and adequate liver function (bilirubin
             level < two times the upper limit of normal, AST and/or ALT < three times the upper
             limit of normal, prothrombin time < 1.5 times control), and creatinine clearance ≥ 60
             ml/min.

          8. Absence of symptomatic CNS metastases (patients with cerebral metastases treated with
             brain irradiation may be included), severe cardiac arrhythmia or heart failure, second
             or third degree heart block or acute myocardial infarction within 4 months prior to
             study entry.

          9. No major surgery or pleurodesis within 14 days prior to enrollment.

         10. Life expectancy of at least 12 weeks.

         11. No previous or concurrent malignancy, except inactive non-melanoma skin cancer, in
             situ carcinoma of the cervix, or other cancer if the patient has been disease-free for
             more than 5 years.

         12. Written informed consent

        Exclusion Criteria:

          1. Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, serious cardiac arrhythmia requiring
             medication, hepatic, renal or metabolic disease).

          2. Patients with clinically significant effusions.

          3. Any other malignancies within 5 years that could affect therapy evaluation
Clinical trial NCT01183481 (phase 2, status: terminated)
Conditions: nausea, vomiting
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: aprepitant, granisetron
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
Reason stopped: 
    study was stopped due to inadequate accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with bone metastases from any primary solid tumor site scheduled to receive a
             single 8 Gy fraction of palliative radiotherapy considered to be moderately emetogenic
             (an area of at least 80 cm2 in the anterior/posterior direction and located between
             the level of upper border of T11 and the lower border of L3) in the RRRP at Sunnybrook
             Odette Cancer Centre will be considered eligible.

        Exclusion Criteria:

          -  Exclusion criteria include having nausea or vomiting 24hrs prior to radiation

          -  Having received or being scheduled to receive cranial radiation, moderately or highly
             emetogenic cytotoxic therapy 7 days prior to, during, or after radiation, receiving
             corticosteroids (except inhaled or topical), 5HT3 receptor antagonists or NK-1
             antagonists or other antiemetic medication, being allergic to study medications,
             having a KPS<40, being pregnant or of childbearing potential and not using
             contraceptive measures.